



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Alogliptin benzoate, Alogliptin benzoate/Pioglitazone hydrochloride, Alogliptin benzoate/Metformin hydrochloride, Tenzeligliptin hydrobromide hydrate, Linagliptin

November 22, 2016

Non-proprietary name

Alogliptin benzoate

Alogliptin benzoate/Pioglitazone hydrochloride

Alogliptin benzoate/Metformin hydrochloride

Tenzeligliptin hydrobromide hydrate

Linagliptin

Safety measure

Precautions should be revised in the package insert.

In the Clinically Significant Adverse Reactions subsection of the Adverse Reactions section, the following text should be added (underlined parts are revised):

Pemphigoid

Pemphigoid may occur. If blister, erosion or other signs and symptoms are observed, patients should be referred to a dermatologist, and appropriate measures such as the discontinuation of administration should be adopted.